$103.06
8.14% yesterday
Nasdaq, May 29, 10:07 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Target price 2025 - Analyst rating & recommendation

Blueprint Medicines Corp. Classifications & Recommendation:

Buy
73%
Hold
23%
Sell
5%

Blueprint Medicines Corp. Price Target

Target Price $125.90
Price $103.06
Potential
Number of Estimates 20
20 Analysts have issued a price target Blueprint Medicines Corp. 2026 . The average Blueprint Medicines Corp. target price is $125.90. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 22 analysts: 16 Analysts recommend Blueprint Medicines Corp. to buy, 5 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2026 of . Most analysts recommend the Blueprint Medicines Corp. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 508.82 721.14
104.03% 41.73%
EBITDA Margin -38.47% -5.61%
79.79% 85.42%
Net Margin -13.19% -6.46%
93.51% 51.01%

20 Analysts have issued a sales forecast Blueprint Medicines Corp. 2025 . The average Blueprint Medicines Corp. sales estimate is

$721m
Unlock
. This is
28.29% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$773m 37.52%
Unlock
, the lowest is
$707m 25.69%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $509m 104.03%
2025
$721m 41.73%
Unlock
2026
$956m 32.53%
Unlock
2027
$1.2b 23.49%
Unlock
2028
$1.4b 21.90%
Unlock
2029
$1.7b 14.96%
Unlock

4 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2025. The average Blueprint Medicines Corp. EBITDA estimate is

$-40.5m
Unlock
. This is
74.45% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$28.1m 117.72%
Unlock
, the lowest is
$-91.8m 42.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-196m 58.76%
2025
$-40.5m 79.33%
Unlock
2026
$127m 414.77%
Unlock
2027
$315m 147.19%
Unlock

EBITDA Margin

2024 -38.47% 79.79%
2025
-5.61% 85.42%
Unlock
2026
13.33% 337.61%
Unlock
2027
26.68% 100.15%
Unlock

20 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2025. The average Blueprint Medicines Corp. net profit estimate is

$-46.6m
Unlock
. This is
70.08% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$104m 166.46%
Unlock
, the lowest is
$-135m 13.36%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-67.1m 86.77%
2025
$-46.6m 30.54%
Unlock
2026
$65.3m 240.04%
Unlock
2027
$233m 256.68%
Unlock
2028
$397m 70.37%
Unlock
2029
$553m 39.51%
Unlock

Net Margin

2024 -13.19% 93.51%
2025
-6.46% 51.01%
Unlock
2026
6.83% 205.73%
Unlock
2027
19.72% 188.73%
Unlock
2028
27.56% 39.76%
Unlock
2029
33.45% 21.37%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.07 -0.72
87.22% 32.71%
P/E negative
EV/Sales 8.97

20 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. EPS is

$-0.72
Unlock
. This is
69.23% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.60 168.38%
Unlock
, the lowest is
$-2.09 10.68%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.07 87.22%
2025
$-0.72 32.71%
Unlock
2026
$1.01 240.28%
Unlock
2027
$3.61 257.43%
Unlock
2028
$6.14 70.08%
Unlock
2029
$8.57 39.58%
Unlock

P/E ratio

Current -44.04 93.20%
2025
-142.79 224.21%
Unlock
2026
101.95 171.40%
Unlock
2027
28.58 71.97%
Unlock
2028
16.78 41.29%
Unlock
2029
12.03 28.31%
Unlock

Based on analysts' sales estimates for 2025, the Blueprint Medicines Corp. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 11.51 46.11%
2025
8.97 22.08%
Unlock
2026
6.77 24.54%
Unlock
2027
5.48 19.02%
Unlock
2028
4.50 17.97%
Unlock
2029
3.91 13.01%
Unlock

P/S ratio

Current 11.84 48.08%
2025
9.23 22.05%
Unlock
2026
6.96 24.54%
Unlock
2027
5.64 19.02%
Unlock
2028
4.63 17.96%
Unlock
2029
4.02 13.01%
Unlock

Current Blueprint Medicines Corp. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked May 02 2025
Needham
Locked
Locked
Locked Apr 28 2025
Wedbush
Locked
Locked
Locked Apr 16 2025
Needham
Locked
Locked
Locked Apr 08 2025
Jefferies
Locked
Locked
Locked Mar 17 2025
Scotiabank
Locked
Locked
Locked Mar 07 2025
Citizens Capital Markets
Locked
Locked
Locked Mar 03 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
May 02 2025
Locked
Needham:
Locked
Locked
Apr 28 2025
Locked
Wedbush:
Locked
Locked
Apr 16 2025
Locked
Needham:
Locked
Locked
Apr 08 2025
Locked
Jefferies:
Locked
Locked
Mar 17 2025
Locked
Scotiabank:
Locked
Locked
Mar 07 2025
Locked
Citizens Capital Markets:
Locked
Locked
Mar 03 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today